<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05088148</url>
  </required_header>
  <id_info>
    <org_study_id>Kutahya Health Sciences Uni</org_study_id>
    <nct_id>NCT05088148</nct_id>
  </id_info>
  <brief_title>Comparison of Pesticide and Pharmaceutical Contaminants Levels in Placenta and Cord Blood Samples of Pregnant Women With Fetal Growth Retardation and Healthy Pregnant Women</brief_title>
  <official_title>Comparison of Pesticide and Pharmaceutical Contaminants Levels in Placenta and Cord Blood Samples of Pregnant Women With Fetal Growth Retardation and Healthy Pregnant Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kutahya Health Sciences University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kutahya Health Sciences University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim: In this study, pesticide and pharmaceutical contaminants levels in the placenta and cord&#xD;
      blood of pregnant women with fetal growth retardation and healthy pregnant women will be&#xD;
      compared in placenta and cord blood samples after delivery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be conducted with a total of 40 pregnant women, 20 of whom are in the control&#xD;
      groups and those with FGR diagnoses. Cases in both groups will be matched in terms of&#xD;
      demographic information. Demographic information (including socioeconomic status, educational&#xD;
      level, region of residence), ultrasound and Doppler examination results, newborn weight at&#xD;
      birth, APGAR score, gender, mode of delivery, whether there is a need for neonatal intensive&#xD;
      care or not will be recorded.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 15, 2021</start_date>
  <completion_date type="Anticipated">November 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Pesticide and Pharmaceutical analysis</measure>
    <time_frame>1 year</time_frame>
    <description>Pesticide and pharmaceutical contaminants levels in pregnant women's placenta and cord blood will be measured in placenta and cord blood samples after delivery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Multi logistic regression analysis.</measure>
    <time_frame>1 month</time_frame>
    <description>If there is a significant difference in other data, including the pesticide and pharmaceutical contaminants levels, in the FGR group, the effect of each factor on the development of FGR will be analyzed by multi logistic regression analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ROC analysis</measure>
    <time_frame>1 month</time_frame>
    <description>If the pesticide and pharmaceutical contaminants levels is found to be significantly higher in the FGR group, the cut-off value will be obtained by ROC analysis.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Fetal Growth Retardation</condition>
  <arm_group>
    <arm_group_label>Group 1: FGR group</arm_group_label>
    <description>Estimated fetal weight &lt;10th percentile</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Control group</arm_group_label>
    <description>Healthy pregnants who will give birth 37th and after gestational week</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>. Pesticide and Pharmaceutical analysis</intervention_name>
    <description>Pesticide and Pharmaceutical analysis will be done with LC-MS/MS device.</description>
    <arm_group_label>Group 1: FGR group</arm_group_label>
    <arm_group_label>Group 2: Control group</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      placenta and cord blood samples of pregnant women&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study will be conducted with a total of 40 pregnant women, 20 of whom are in the&#xD;
        control groups and those with FGR diagnoses. Cases in both groups will be matched in terms&#xD;
        of demographic information. Demographic information (including socioeconomic status,&#xD;
        educational level, region of residence), ultrasound and Doppler examination results,&#xD;
        newborn weight at birth, APGAR score, gender, mode of delivery, whether there is a need for&#xD;
        neonatal intensive care or not will be recorded.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Between the ages of 18-40 years&#xD;
&#xD;
          -  Gestational age between 320/7 - 396/7 weeks&#xD;
&#xD;
          -  Singleton pregnancy&#xD;
&#xD;
          -  For the FGR group: estimated fetal weight &lt;10th percentile&#xD;
&#xD;
          -  For the control group: being healthy pregnant&#xD;
&#xD;
          -  Intact amniotic membrane&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Multiple pregnancies&#xD;
&#xD;
          -  Cardiovascular disease&#xD;
&#xD;
          -  Chronic hypertension&#xD;
&#xD;
          -  Autoimmune disease&#xD;
&#xD;
          -  Intrahepatic cholestasis of pregnancy&#xD;
&#xD;
          -  Preeclampsia-eclampsia&#xD;
&#xD;
          -  Sepsis&#xD;
&#xD;
          -  Placenta accreta spectrum&#xD;
&#xD;
          -  Abnormalities of placenta&#xD;
&#xD;
          -  The chromosomal or congenital structural anomaly of the fetus&#xD;
&#xD;
          -  Smoking&#xD;
&#xD;
          -  BMI &gt;30 kg/m2&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Pregnant</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 11, 2021</study_first_submitted>
  <study_first_submitted_qc>October 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 21, 2021</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fetal Growth Retardation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

